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Introduction {#sec005}
============

In Africa, over the past decade a remarkable increase in access to combination antiretroviral therapy (cART) has been continued and has substantially contributed to the dramatic reduction in morbidity and mortality. It has also improved quality of life and life expectancy and altered perceptions on HIV/AIDS from an epidemic to a manageable chronic illness \[[@pone.0186619.ref001], [@pone.0186619.ref002]\]. These achievements are based on the WHO public health approach of using clinical and immunological parameters as the standard for ART initiation and monitoring, despite its limitations compared with the reference virological parameters based approach \[[@pone.0186619.ref003], [@pone.0186619.ref004]\]. The exclusive use of this simplified strategy to initiate and switch ART together with the use of drugs with low-genetic-barrier and the socio-cultural issues in the region may favor the rapid emergence, accumulation and transmission of resistant viruses.

Along with the expanded coverage of ART, prevalence of transmitted drug resistance (TDR) is rising overtime \[[@pone.0186619.ref005]--[@pone.0186619.ref007]\] predominantly associated with nonnucleoside reverse transcriptase inhibitors (NNRTIs). Moreover, few available studies on long term virological outcomes showed that virological failure remains undetected and patients continue to be on failing regimen until either clinical or immunological failure occurs \[[@pone.0186619.ref008]\] which leads to high rates of treatment failure with virological failure rates of greater than 20% after 24 months of ART and development of resistance with the potential of reducing the efficacy of available first-line regimens \[[@pone.0186619.ref008], [@pone.0186619.ref009]\] in up to 90% of patients and being considered as a major threat for ongoing and future treatment options\[[@pone.0186619.ref008]--[@pone.0186619.ref012]\]. Although many studies have reported early outcomes of patients on ART, they were limited to patient's outcomes in terms of retention and survival \[[@pone.0186619.ref013]\] without baseline virological data.

In Ethiopia, according to the recent report from the Federal HIV Prevention and Control Office, there are about 740,000 people living with HIV in Ethiopia, and only 400,000 are receiving antiretroviral treatment. Previous studies in early years of HIV and recent studies including our previous works show the presences of HIV-1C clade homogeneity in 99% of Ethiopian isolates \[[@pone.0186619.ref014]\]. ART in Ethiopia consists of generic low cost fixed-dose combination (FDC) of two NRTI and

one NNRTI with first line regimens of lamivudine (3TC) combined with stavudine (d4T) or zidovudine (AZT), and either nevirapine (NVP) or efavirenz (EFV) permitting four alternative treatment regimens: D4T+3TC+NVP; D4T+3TC+EFV; ZDV+3TC+NVP; or ZDV+3TC+EFV. For second line therapy, the nucleoside backbone is changed to ABC, TDF, ddI or ZDV (if not used in first-line therapy); and, in addition, the non-nucleoside reverse transcriptase inhibitors (NNRTIs) NVP or EFV was replaced by one of the boosted protease inhibitors (PIs) lopinavir (LPV/r), saquinavir (SQV/r) or indinavir (IND/r) \[<https://aidsfree.usaid.gov/>\]. Although D4T has been omitted from ART recommendations because of its side effects in 2008, it is still used extensively in Ethiopia. ART initiation and monitoring is based on the WHO clinico-immunological approach. However, as this approach lacks viral load determination and drug resistance testing HIV infected individuals may be at risk for "unrecognized" virologic failure and the subsequent development of antiretroviral drug resistance.

In this a decade longitudinal study, we aimed to determine the incidence of virological failure and acquired drug resistance mutations overtime and to identify the most common mutational pathways of resistance among two groups of patients who had initiated ART at the scale-up (2008)-Group 1 and first roll out (2005)---Group 2 of ART in a well characterized HIV-1C infected Ethiopian cohort \[[@pone.0186619.ref003], [@pone.0186619.ref004], [@pone.0186619.ref014]\].

Methods {#sec006}
=======

Study design {#sec007}
------------

This is a prospective cohort study where the baseline characteristics \[[@pone.0186619.ref003], [@pone.0186619.ref014]\] of the groups and the outcome of ART after a median time of 30 months \[[@pone.0186619.ref004]\] have been described before. The cohort profile is depicted in [Fig 1](#pone.0186619.g001){ref-type="fig"} The study protocol and design including the consent procedures were approved by the University of Gondar Ethical Review Committee (RPO/55/291/00).

![Cohort profile.](pone.0186619.g001){#pone.0186619.g001}

Treatment and patients monitoring {#sec008}
---------------------------------

As described before \[[@pone.0186619.ref003], [@pone.0186619.ref004], [@pone.0186619.ref014]\], patients were evaluated with a standardized form at enrolment and diagnosed based on the WHO criteria of AIDS-defining conditions. Although, the eligibility criterion for ART has been changed over the years the initial criteria based on CD4 count \<200 cells/mm^3^or WHO stage 4 was used \[[@pone.0186619.ref013]\].

Blood collection and laboratory investigations {#sec009}
----------------------------------------------

Sample collection and preparation, CD4^+^ T cells count, HIV-1 RNA extraction, pol gene amplification and sequencing were done as described previously \[[@pone.0186619.ref003], [@pone.0186619.ref004], [@pone.0186619.ref014]\]. Briefly, blood samples was collected in vacutainer tubes containing ethylene diamine tetraacetic acid (EDTA) at baseline, every 6 months (for CD4^+^ T cells count only) and at last by a median time of 24 months on ART for viral load determination and detection of drug resistance mutations. Immunological failure was defined as failure to achieve a CD4^+^ T cells gain of at least 50 cells above pre-therapy level or having an absolute CD4^+^ T cells count of \< 100 cells/mm^3^ after one year of therapy \[[@pone.0186619.ref015]\].

A baseline blood samples refers to a blood sample collected prior to the initiation of ART and denoted by T0 (2008). The time point T1 was a blood sample collected in a median time of 30 months on ART (2011) and the time points T2 (2013) and T3 (2015) were blood samples collected at least in a median time of 24 months. Thus, HIV viral load was measured at T0 (N = 220), T1 (N = 127), T2 (N = 101) and T3 (N = 72) for Group-2 and at T1 (N = 100), T2 (N = 67) and T3 (N = 44) for Group-1 patients. Although, WHO defines virological failure using viral load cut-offs of \> 3log copies/ml after 3 months with adherence support \[[@pone.0186619.ref015]\], there is no standardized reporting of virologic failure since 3 months may not enough for full viral suppression and since resistance mutations could be detected in samples with VL of as low as 2.5log copies/ml and not in patients with viral load of \>1000 copies/ml. Thus, in this study viral load of below the detection limits of the assay (1.6log copies/ml), between 1.6 and 2.6log copies/ml and \>2.6log copies/ml in single plasma sample were defined as virologic suppression, low-level viremia and virological failure, respectively \[[@pone.0186619.ref016]\]. Genotypic drug resistance mutations were interpreted according to the Stanford University drug resistance database (<http://hivdb.stanford.edu>) and the 2017 IAS mutation list \[[@pone.0186619.ref017]\]. The Stanford HIV Drug Resistance Database (HIVDB) mutation penalty scoring system (<http://hivdb.stanford.edu/DR/>) was also used to estimate genotypic susceptibility scores (GSSs) and characterize the level of resistance in clinical isolates. HIV-1 subtype was determined by using the REGA HIV-1 Automated Subtyping Tool version 2 (<http://www.bioafrica.net>).

Results {#sec010}
=======

Cohort characteristics of Group 1 {#sec011}
---------------------------------

The level of transmitted drug resistance at baseline (T0) was found to be 5.6% and 13.1% according to the Stanford University HIVDB drug resistance interpretation algorithms and the International Antiviral Society mutation lists, respectively ([S1 Table](#pone.0186619.s001){ref-type="supplementary-material"}). Furthermore, viral suppression rate after a median time of 30 months on ART (T1) was found to be 88.2% (112/127). Among the 15 virologically failed patients, six harbored one or more drug resistant associated mutations in the reverse transcriptase region ([S2 Table](#pone.0186619.s002){ref-type="supplementary-material"}).

Incidence of virological failure {#sec012}
--------------------------------

In this study, by the time point T2 (after 5 years on ART) and T3 (after 8 years on ART), 72% (101/140) and 71% (72/101) were found to be active on ART program. At T2, among those on ART a total of 83% (84/101) achieved virological suppression which with time decreased to 70% (51/72) by the time point T3. In another words, the incidence of virological failure has increased overtime from 11% at T1 \[[@pone.0186619.ref004]\] to 17% at T2 and then to 30% at T3 ([Fig 2](#pone.0186619.g002){ref-type="fig"}). Moreover, an increasing median HIV-1 RNA level in virologically failed subjects was observed over time (4.28, 4.42 and 5.4log10 copies/ml at T1, T2 and T3, respectively. Elven out of 15 (73%), 11/17 (64%) and 15/21(71%) of the patients with cohort definition of VF (above 1.6log10 copies/ml) met the WHO virological failure criteria (\>3log10 copies/ml) at time point T1, T2 and T3, respectively. However, at all time points almost all of the patients with virological failure and accumulated drug resistance mutations had not met the WHO clinical and immunologic failure criteria and continued the failing regimen although a reduction in CD^+^4 T cell counts is noted (Tables [1](#pone.0186619.t001){ref-type="table"} and [2](#pone.0186619.t002){ref-type="table"}). At time point T1 drug resistance mutations were not detected in 2 patients despite high viral load ([S2 Table](#pone.0186619.s002){ref-type="supplementary-material"}). This phenomenon was seen in 6 patients each at time point T2 ([Table 1](#pone.0186619.t001){ref-type="table"}) and T3 ([Table 2](#pone.0186619.t002){ref-type="table"}). About a quarter of the patients who did not reach virological suppression at T2 and T3 had had a low-level viremia at the preceding time points.

![Incidence of virological failure and acquired drug resistance over time.](pone.0186619.g002){#pone.0186619.g002}

10.1371/journal.pone.0186619.t001

###### Clinical characteristics and antiretroviral drug resistance mutation (at time point-T2).

![](pone.0186619.t001){#pone.0186619.t001g}

  ID     Age[\*](#t001fn001){ref-type="table-fn"}/Sex   CD4^+^ cells   HIV-1 RNA   ART Regimen[^1^](#t001fn006){ref-type="table-fn"}   Time   NRTIs   NNRTIs                                                                                                                                                
  ------ ---------------------------------------------- -------------- ----------- --------------------------------------------------- ------ ------- -------- ---- ---- ---- ---- ----------------------------------------------------- ------------------------------------- ---------------------------- ----------------------
  0003   48/M                                           251            291         221                                                 5.91   ud      6.04     1a   1a   1a   68   M184V, V75I, K65R, Y115F                              3TC, FTC, ABC, TDF, D4T               K103N,L100I, V179T           EFV, NVP, RPV, *ETR*
  0005   38/M                                           201            249         211                                                 3.85   ud      5.63     1a   1a   1c   63   M184V, T215Y                                          3TC, FTC, ABC, TDF, *AZT*, *D4T*      V106V, F227L                 EFV, NVP
  0006   43/F                                           81             378         289                                                 5.04   ud      5.50     1a   1c   1a   62   None                                                  \-                                    Y181L, P225H                 EFV, NVP, RPV
  0009   48/F                                           178            347         293                                                 4.50   ud      5.69     1a   1c   1a   60   K65R                                                  TDF, DDI, *ABC*, *D4T*                K103N, V106M                 EFV, NVP
  0013   38/F                                           184            299         168                                                 4.05   ud      3.92     1a   1a   1c   67   K65R, Y115F, M184V                                    3TC, FTC, ABC, TDF, D4T, FTC, *D4T*   K101E, Y181C, G190A          EFV, NVP, RPV, ETR
  0014   38/F                                           76             399         383                                                 4.31   2.65    4.63     1a   1a   1a   66   M184V                                                 3TC, FTC                              K103N, E138K, P225H, K238T   EFV, NVP, ETR, *RPV*
  0017   44/F                                           84             357         121                                                 5.79   ud      5.37     1a   1b   1d   69   E44A, L74I, K70R, M184V, V118I, T215V, K219E, L210W   3TC, ABC, AZT, D4T, DDI, FTC, *TDF*   K103N                        EFV, NVP
  0018   35/F                                           149            358         277                                                 5.01   2.57    5.79     1a   1a   1d   59   M184I, L74I, D67N                                     3TC, ABC, D4T, FTC                    G190E                        EFV, NVP, RPV, ETR
  0019   49/F                                           293            421         302                                                 5.43   ud      6.04     1a   1a   1c   65   M184I, L74I, D67N                                     3TC, ABC, D4T, FTC                    V90I, G190E                  EFV, NVP, RPV, ETR
  0039   47/M                                           181            396         417                                                 4.42   ud      4,46     1a   1c   1c   64   T69D                                                  DDI                                   None                         \-
  0035   39/M                                           219            467         311                                                 3.03   2.19    5.30     1a   1c   1c   62   D67N, T69D, K70R, M184V, K219Q                        3TC, DDI, FTC, *ABC*, *AZT*, *D4T*    V106M, Y188C                 EFV, NVP
  0001   39/M                                           189            356         341                                                 5.34   ud      3.74     1a   1a   1c   58   None                                                  \-                                    None                         \-
  0004   43/M                                           162            325         299                                                 5.56   ud      4,66     1a   1a   1c   61   None                                                  \-                                    None                         \-
  0007   41/M                                           195            399         311                                                 4.98   2.39    3.93     1b   1b   1c   57   None                                                  \-                                    None                         \-
  0011   37/M                                           230            379         302                                                 6.12   ud      2.19     1a   1c   1c   67   None                                                  \-                                    None                         \-
  0020   45/F                                           211            496         349                                                 5.29   ud      5.60     1b   1c   1c   67   None                                                  \-                                    None                         \-
  0022   29/F                                           165            389         377                                                 5.47   ud      5.19     1b   1c   1c   59   None                                                  \-                                    None                         \-

\* Age (years) is at time point (T2);

CD4 T cells/mm3;

HIV-1 RNA log10 copies/ml;

Time on ART (months);

ud: HIV RNA\< 1.6log10 copes/ml;

^1^1a: 3TC---d4T + NVP; 1b: 3TC---d4T + EFV; 1c: 3TC---AZT+ NVP; 1d: 3TC---AZT + EFV;

^2^3TC (Lamivudine), d4T (Stavidine), NVP (Nevirapine), EFV (Efavirenz), AZT (Zidovidine); Intermediate Level of Resistance to the drugs in *italic* type.

10.1371/journal.pone.0186619.t002

###### Clinical characteristics and antiretroviral drug resistance mutation (at time point- T3).

![](pone.0186619.t002){#pone.0186619.t002g}

  ID     Age[\*](#t002fn001){ref-type="table-fn"}/Sex   CD4^+^ T   HIV RNA   ART[^1^](#t002fn006){ref-type="table-fn"}   Time   NRTI   NNRTI                                                                                                                                                     
  ------ ---------------------------------------------- ---------- --------- ------------------------------------------- ------ ------ ------- ------ ------ ---- ---- ---- ---- ---- -------------------------------- -------------------------------------- ---------------------------------- --------------------------
  0023   51/M                                           210        342       388                                         291    4.43   ud      ud     5.59   1a   1a   1a   1a   65   M184V, M41L, T215I               3TC, FTC, *ABC*, *AZT*, *D4T*, *DDI*   K101Q, V106A, F227L                EFV, NVP
  0026   28/M                                           201        287       345                                         149    4.17   ud      ud     3.46   1a   1a   1a   1a   67   M184I                            3TC, FTC                               V106M, G190A, V179D, F227L, V90I   EFV, NVP, ETR, *RPV*
  0027   25/F                                           229        367       411                                         293    5.43   ud      2.58   5.10   1c   1c   1c   1c   56   M184V, D67N, K70R, T69D, K219Q   3TC, DDI, FTC, *ABC*, *AZT*, *D4T*     V106M, Y188C                       EFV, NVP
  0028   29M                                            199        325       412                                         181    4.42   ud      ud     5.16   1c   1c   1c   1c   59   D67N, T69D, K70R, M184V, K219Q   3TC, DDI, FTC, *ABC*, *AZT*, *D4T*     V106M, Y188C                       EFV, NVP
  0030   38/F                                           274        378       411                                         219    3.03   ud      2.59   5.36   1c   1c   1c   1c   66   M184V, K70R                      3TC, FTC, *ABC*                        G190A, K101E, Y181C, H221Y         EFV, NVP, ETR, RPV
  0032   30/M                                           32         149       301                                         199    3.76   ud      ud     4.37   1c   1c   1c   1c   54   K65R, Y115F, M184V               3TC, ABC, DDI, FTC, TDF, *D4T*         Y181C                              NVP, *EFV*, *ETR*, *RPV*
  0033   28/M                                           191        289       389                                         357    4.43   ud      ud     4.96   1c   1c   1c   1c   67   K70E, L74I, Y115F, M184V         3TC, ABC, DDI, FTC, *TDF*              V106M, V179D, H221Y, F227L         EFV, NVP
  0034   25/F                                           149        276       432                                         458    4.17   ud      2.42   6.47   1d   1d   1d   1d   71   D67N, K70R, M184V, T69Q, K219Q   3TC, DDI, FTC, *ABC*, *D4T*, *AZT*     V106M, Y188C                       EFV, NVP
  0037   38/F                                           181        265       378                                         396    4.42   ud      2.54   6.20   1d   1d   1d   1d   63   D67N, T69D, K70R, M184V, K219Q   3TC, DDI, FTC, *ABC*, *D4T*, *AZT*     V106M, Y188C                       EFV, NVP
  0040   30/M                                           219        329       399                                         467    3.03   ud      ud     2.94   1a   1a   1a   1a   59   K70R, M184V                      3TC, FTC                               V106M, Y188C                       EFV, NVP
  0041   51/M                                           258        287       381                                         291    4.43   ud      ud     3.04   1b   1b   1b   1b   57   D67N, T69D, K70R, M184V, K219Q   3TC, FCT, DDI, *ABC*, *D4T*, *AZT*     V106M, Y188C                       EFV, NVP
  0046   28/F                                           198        342       358                                         349    4.17   ud      ud     2.67   1c   1c   1c   1c   72   M184V                            3TC, FTC                               K103N                              EFV, NVP
  0052   25/F                                           149        276       276                                         293    5.43   ud      ud     3.99   1c   1c   1c   1c   69   None                             \-                                     K103N                              EFV, NVP
  0012   25/F                                           62         345       341                                         270    2.20   ud      ud     3.00   1a   1a   1a   1a   61   None                             \-                                     K103N                              EFV, NVP
  0008   29/F                                           193        257       349                                         421    5.43   ud      ud     2.94   1a   1a   1a   1a   66   None                             \-                                     K103N                              EFV, NVP
  0024   37/F                                           176        267       421                                         476    5.44   ud      2.50   5.59   1b   1b   1b   1b   69   None                             \-                                     None                               \-
  0025   41/M                                           169        325       388                                         347    4.78   ud      ud     3.00   1c   1c   1c   1c   70   None                             \-                                     None                               \-
  0029   38/F                                           201        298       349                                         399    4.99   ud      2.25   5.45   1c   1c   1c   1c   57   None                             \-                                     None                               \-
  0031   35/M                                           69         178       289                                         364    6.20   ud      ud     4.23   1c   1c   1c   1c   62   None                             \-                                     None                               \-
  0038   45/F                                           196        287       388                                         345    4.77   ud      ud     3.14   1d   1d   1d   1d   68   None                             \-                                     None                               \-
  0054   39/M                                           184        321       428                                         369    5.22   ud      ud     4.28   1c   1c   1c   1c   62   None                             \-                                     None                               \-

\* Age (years) is at time point (T2);

CD4 T cells/mm3;

HIV-1 RNA log10 copies/ml;

Time on ART (months);

ud: HIV RNA\< 1.6log10 copes/ml;

^1^1a: 3TC---d4T + NVP; 1b: 3TC---d4T + EFV; 1c: 3TC---AZT + NVP; 1d: 3TC---AZT + EFV;

^2^3TC (Lamivudine), d4T (Stavidine), NVP (Nevirapine), EFV (Efavirenz), AZT (Zidovidine); Intermediate Level of Resistance to the drugs in *italic* type.

Incidence of acquired drug resistance mutation {#sec013}
----------------------------------------------

None of the patients who had acquired drug resistance associated mutations had presented pre ART drug resistance mutations suggesting that these mutations are developed after treatment initiation and are definitely acquired with obvious limitation of population based sequencing which miss minority resistant variants. There was high sequence similarity and strong clustering between plasma samples of individual patients at different time points (Data not shown). Among individuals with virological failure a steep increase in the incidence of accumulation of major acquired NRTI and NNRTI drug resistance mutations have been observed overtime (from 40% (6/15) at T1 to 64% (11/17) at T2 and then to 66% (15/21) at T3 ([Fig 2](#pone.0186619.g002){ref-type="fig"}).

At baseline (T0), 4 NRTIs transmitted drug resistance associated mutations were observed. By the time point T1, 5 NRTIs associated mutations were observed which then increased substantially to 28 by the time point T2 and further increased to 40 by the time point T3 ([Fig 3](#pone.0186619.g003){ref-type="fig"}).

![Accumulation of acquired drug resistance mutations over time.](pone.0186619.g003){#pone.0186619.g003}

The most frequent NRTIs drug resistance associated mutation is mainly lamivudine-induced mutation M184V which was detected in 4 patients at T1 and showed a 2 fold increase in the following time points (T2: n = 8) and at (T3: n = 12). The occurrence of thymidine analogue mutations (TAMs) were not-detected at baseline T0 and T1 but was increased progressively to 10 at T2 and to 17 at T3. Among the two TAMs pathways, TAM-2 which features D67N, K70R, T215F, and K219E/Q mutations was more common than the TAM-1 which features M41L, L210W and T215Y. Most of the patients with multiple TAMs were on d4T or AZT containing regimen (Tables [1](#pone.0186619.t001){ref-type="table"} and [2](#pone.0186619.t002){ref-type="table"}). At all-time points, relatively low frequency of K65R mutation was found ([Fig 3](#pone.0186619.g003){ref-type="fig"}). Mutations conferring multi-drug resistance such as Q151M and T69ins were not detected. However, additional mutational pathway at codon 69 from T to D known to reduce susceptibility to D4T and DDI has been observed at time point T2 (n = 3) and T3 (n = 4) ([Fig 4a](#pone.0186619.g004){ref-type="fig"}).

![Accumulation of NRTI (a) & NNRTIs (b) associated acquired drug resistance mutations over time.](pone.0186619.g004){#pone.0186619.g004}

At baseline (T0), 5 NNRTIs transmitted drug resistance associated mutations were observed. At T1, the NNRTIs resistance associated mutations were detected at a lower frequency \[K103N (n = 2), V106M, Y181S, Y188L, V90I, K101E and G190A (n = 1 each)\]. But with time like NRTIs, the frequency and pattern of NNRTIs associated mutations increased significantly. Briefly, by the time point T1, 8 NNRTIs associated mutations were observed which then increased substantially to 18 by the time point T2 and further increased to 26 by the time point T3 ([Fig 3](#pone.0186619.g003){ref-type="fig"}). The most frequent

Dual-class resistance to NRTIs and NNRTIs were not detected at baseline T0 ([S1 Table](#pone.0186619.s001){ref-type="supplementary-material"}). But eventually observed in 5/8, 8/11 and 12/15 patients at time point T1 ([S2 Table](#pone.0186619.s002){ref-type="supplementary-material"}), T2 ([Table 1](#pone.0186619.t001){ref-type="table"}) and T3 ([Table 2](#pone.0186619.t002){ref-type="table"}), respectively with frequent combination of M184V and NNRTI resistance associated mutations. Most of the viral isolates had developed resistance to drugs that the patients were receiving frequently for NRTIs like lamuvidine/emtricitabine, zidovidine, stavudine or tenofovir and for NNRTIs like nevirapine or efavirenz. But still few isolates had reduced susceptibility or resistant to other drugs that the patients did not receive (Tables [1](#pone.0186619.t001){ref-type="table"} and [2](#pone.0186619.t002){ref-type="table"}).

Major drug resistance mutations on PR region were not detected at all time points. However, in the majority of the patients at all time points, several secondary mutations that may facilitate the development of PI resistance were found at higher frequency which could be naturally occurring minor mutations/polymorphic changes (positions M36I, R41K, H69K, L89M, and I93L) but their clinical significance is uncertain. Seven out of eleven at T1 and 9/15 at T2 who had treatment switch to second line ART (PI/r + 2NRTIs regimen) were found to be virologically suppressed.

Genotypic susceptibility score (GSS) {#sec014}
------------------------------------

At baseline, most of the viral isolates were fully susceptible for the available NRTIs and NNRTIs. However, the mean GSS for both all NRTIs and NNRTIs decreased overtime and the number of treatment option decreased overtime with viremia. [Fig 5](#pone.0186619.g005){ref-type="fig"} shows the predicted genotypic drug susceptibility score of the available drugs in the clinical settings. For example susceptibility score of the common NNRTIs EFV has significantly reduced from 100% at baseline to 15% by the time point T3. On the other hand, among 100 consecutive HIV-1 infected adults who have been receiving ART since 2005 (Grroup-1), virological suppression at time point-T0 was observed in 82% of the patients on a median time of 24 months on ART \[[@pone.0186619.ref003]\]. Among the virological failed patients only one patient had K103N mutation which confers resistance to NNRTIs \[[@pone.0186619.ref003]\]. By a median time of 5 years on ART (in 2011), 76% of the patients were on ART of which 93% (71/76) were virologically suppressed. Again, by the median time of 8 years (in 2013) and 10 years (in 2015) years on ART, 94% (51/54) and 93% (29/31) of the patients, respectively were virologically suppressed. That means, the incidence of virological failure was almost stable overtime. Moreover, those who did not reach to virological suppression level had a low level viremia ranging from 1.7 to 2.5log~10~ copies /ml.

![Predicted genotypic drug resistance susceptibility score over time.\
Keys: NNRTIs-efavirenz (EFV), etravirine (ETR), nevirapine (NVP), rilpivirine (RPV); NRTIs-lamuvidine (3TC), abacavir (ABC), zidovudine (AZT), stavudine (D4T), didanosine (ddl), emtricitabine (FTC), tenofovir (TDF).](pone.0186619.g005){#pone.0186619.g005}

Discussion {#sec015}
==========

This study describes a decade virological outcomes and measures the incidence of virological failure and acquired drug resistance mutations in Ethiopian HIV-1C infected adults at 4 time points from the Horn of Africa. The study has the following main findings in relation to the incidence of virological failure, accumulation of acquired drug resistance mutations and the pattern of mutational pathways.

First, a relative upward trend in the incidence of both virological failure and acquired drug resistance mutation driven by NRTIs and NNRTIs is observed over the years supporting the notion that prolonged exposure to ART drives the emergence of mutant variants \[[@pone.0186619.ref005], [@pone.0186619.ref016]\] and are consistent with studies from other African countries where a significant increase in rate of both virological failure and drug resistance overtime since rollout of ART has been observed \[[@pone.0186619.ref009], [@pone.0186619.ref012], [@pone.0186619.ref016]--[@pone.0186619.ref021]\] and initial reports from resource reach countries \[[@pone.0186619.ref022]\]. Considering recent findings from the country that shows nearly 50% of patients on ART continue to engage in risky sexual practice \[[@pone.0186619.ref023]--[@pone.0186619.ref025]\], the increasing rate of virological failure with increased level of viremia may have an impact not only on increasing overall risk of HIV transmission at a population level but also on increasing rate of reinfection by resistant strains. Thus, both population-level and patients targeted interventions to reduce risky sexual behavior is warranted.

The higher rate of NRTI resistance may reflect the expected pattern of mutations with increasing use of first line therapy \[[@pone.0186619.ref026]\]. Moreover, the increasing accumulation rate of acquired drug resistance mutations could be due to the fact that almost all of the patients with virologic failure and drug resistance mutations had not met the WHO clinical and/or immunological failure criteria and continued the failing regimen and are consistent with recent findings which show a 30% per year increase in drug resistance in east Africa \[[@pone.0186619.ref019]\]. However, there is a significant difference in rate of virological failure and accumulation of drug resistance mutation among those who initiated ART at roll out (the first group of patients receiving cART in Ethiopia) and scale up of ART. This heterogenecity among these group of patients could be associated with task-shifting approach from more specialized (roll out of ART) to less specialized (scaling-up of ART) health workers although our study and previous studies showed that the latter is non-inferior to the former \[[@pone.0186619.ref013], [@pone.0186619.ref027], [@pone.0186619.ref028]\] in terms of care during the clinical visits and retention in ART care. The influence of task-shifting approaches on virological outcomes is not well examined and could result variation monitoring of ART and possibly influence patient's adherence although overall adherence in this particular study and other several studies from sub-Saharan Africa is not worse compared to western countries \[[@pone.0186619.ref013], [@pone.0186619.ref028]\]. Thus, other drug related factors such as drug supply and regimens used \[[@pone.0186619.ref008]\] and local programmatic factors such as when to start/switch, what to start/switch, lack of access for viral load and resistance testing, lack of alternative drugs with high genetic barriers could have also contributed to the observed difference.

Second, the absence of major protease inhibitors drug resistant mutations in this cohort could explain the relation between drug access and emergence of drug resistant mutations. This could reflect the presence of limited access of the drug class in the country as less than 2% of patients are taking drug regimens containing this drug class. The occurrence of naturally occurring polymorphic changes on PR region may have clinical relevance as these changes may result in the evolution of drug resistance along distinct mutational pathways, or in the incidence of different pathways when considering long-term treatment strategies of HIV-1C infected patients with PI based regimen \[[@pone.0186619.ref029]\]. A rapid increase in lamivudine and TAMs were noted and could be associated with the extensive use of thymidine analogues and their eventual accumulation overtime in Africa as patients continue failing regimen which might reduce the effectiveness of second line TDF containing combinations. These findings are important in view of the fact that following WHO recommendations TDF is replacing thymidine analogues, phasing out of the nevirapine from first line regimens and considering LPV/r-based regimen as the PI of choice in second-line treatment in Africa. In this cohort empirical switching to second line therapy in small number of patients with failing regimen and existence of drug resistance mutations led to effective viral suppression demonstrating that TDF containing and PI-based second line regimens can successfully re-suppress NRTI and NNRTI resistant HIV mutants and improves virological outcomes. Thus, to preserve this recent WHO recommendation and to protect resistance development against TDF and PIs, pre-ART resistance testing for key NNRTI and PI mutations could be considered. Third, the failure of the WHO public health clinical and immunological approaches in detecting treatment failure support the recent WHO recommendation for HIV-1 viral load testing in Africa \[[@pone.0186619.ref015]\] but yet less than 2% of patients had VL tested \[[@pone.0186619.ref022]\] and still in some countries like Ethiopia non-existing in routine clinical practice.

Lastly, the study in one side identified an increasing common mutational pathways overtime with two thymidine non-analog (M184V and K65R) and three thymidine analog (D67N, K70R and K219E) major nucleoside reverse transcriptase inhibitor (NRTI)-associated DRMs and four major NNRTI-associated DRMs (K103N, Y181C, G190A, and V106M) which is consistent with previous studies \[[@pone.0186619.ref020], [@pone.0186619.ref029]\]. But on the other side, a stable rate of selection was also observed for some NRTI mutations (such as Y115F, L210W) and several NNRTI mutations (such as L100I, K101E, P225H and M230L). Thus, the first common mutational pathways could be important for designing a point of care genotypic resistance test as suggested before \[[@pone.0186619.ref030]\] and would be useful in the region.

Conclusions {#sec016}
===========

In summary, an upward trend of both virological failure and NRTI and NNRTI associated drug resistance acquired drug resistance mutations has been observed overtime. The findings indicate that ART programs in east Africa could not achieved WHO suggested targets of long term virological suppression overtime. Thus, regional focused strategies to decrease the rate of virological failure and acquired drug resistance, to prevent the spread of mutant variants, to increase access for TDF, PI drugs, HIV viral load and resistance testing are needed if the 90-90-90 targets are to be attained. As a result treatment success of current first-line ART could be improved, the efficacy of second-and third-line therapies could be preserved and transmission of resistant variants which could be the future challenge of the region unless controlled early could be prevented.
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